Eli Lilly’s marketed obesity drug Zepbound produced greater clinical benefit than Novo Nordisk’s GLP-1/amylin combo CagriSema in the head‑to‑head REDEFINE 4 trial, Novo reported. The company disclosed that CagriSema failed to match weight‑loss outcomes versus Lilly’s product in the randomized study. The result represents an immediate commercial and development setback for Novo Nordisk’s combination approach and reinforces Lilly’s leading position in the obesity therapeutic market. REDEFINE 4 is a direct comparative efficacy readout — the kind of data that can shift prescribing decisions and commercialization strategies. Investors and pipeline teams should watch how Novo adjusts its program timing, regulatory positioning and messaging for CagriSema after these head‑to‑head data.